An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Celgene
- Target Recruit Count
- 21
- Registration Number
- NCT03900715
- Locations
- 🇯🇵
Local Institution - 344, Nagasaki-shi, Nagasaki, Japan
🇯🇵Local Institution - 331, Kamogawa, Japan
🇯🇵Local Institution - 348, Kitakyushu, Japan
A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 90
- Registration Number
- NCT03850067
- Locations
- 🇪🇸
Local Institution - 406, Majadahonda, Madrid, Spain
🇫🇷Local Institution - 102, Marseille Cedex 5, France
🇪🇸Local Institution - 402, Barcelona, Spain
Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Celgene
- Target Recruit Count
- 40
- Registration Number
- NCT03824678
- Locations
- 🇺🇸
Orlando Clinical Research Center OCRC, Orlando, Florida, United States
🇺🇸The Texas Liver Institute, San Antonio, Texas, United States
🇺🇸Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy Subjects
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 56
- Registration Number
- NCT03803644
- Locations
- 🇺🇸
Covance-Daytona Beach, Daytona Beach, Florida, United States
A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
- Conditions
- Interventions
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Celgene
- Target Recruit Count
- 230
- Registration Number
- NCT03783403
- Locations
- 🇺🇸
Local Institution - 107, Pittsburgh, Pennsylvania, United States
🇺🇸Local Institution - 108, Houston, Texas, United States
🇺🇸Local Institution - 103, San Antonio, Texas, United States
A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
- Conditions
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 38
- Registration Number
- NCT03755518
- Locations
- 🇺🇸
Local Institution - 123, Baltimore, Maryland, United States
🇨🇦Local Institution - 200, Toronto, Ontario, Canada
🇺🇸Local Institution - 112, Chicago, Illinois, United States
A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1
- Registration Number
- NCT03745222
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
🇺🇸Dayton Physicians, LLC, Kettering, Ohio, United States
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
- Conditions
- Interventions
- First Posted Date
- 2018-11-16
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Celgene
- Target Recruit Count
- 21
- Registration Number
- NCT03743246
- Locations
- 🇺🇸
Local Institution - 167, Redwood City, California, United States
🇺🇸Local Institution - 161, Seattle, Washington, United States
🇺🇸Local Institution - 165, Houston, Texas, United States
A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Celgene
- Target Recruit Count
- 40
- Registration Number
- NCT03742882
- Locations
- 🇺🇸
Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville, Knoxville, Tennessee, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸The Texas Liver Institute, San Antonio, Texas, United States
ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Celgene
- Target Recruit Count
- 150
- Registration Number
- NCT03742921
- Locations
- 🇯🇵
Nihon Seimei Hospital, Osaka, Japan